Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | BMC Musculoskeletal Disorders

Figure 1

From: Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis

Figure 1

Patient disposition. Following an announcement of a possible increase in CV risk with celecoxib, some patients withdrew consent (4%) and some (12.9%) were discontinued after a protocol amendment excluded patients with an elevated CV risk or a history of CV or cerebrovascular disease; o.d. = once daily; b.i.d. = twice daily; ITT = intention-to-treat.

Back to article page